• Haemonetics Corporation recently reported its fourth-quarter and full-year 2026 results, with quarterly sales rising to US$346.35 million but swinging from net income of US$57.98 million a year earlier to a net loss of US$20.15 million, while full-year sales edged down to US$1.33 billion and net income fell to US$97.31 million.
• Despite the weaker GAAP results, Haemonetics delivered adjusted revenue and earnings above analyst expectations and outlined fiscal 2027 guidance that emphasizes organic revenue growth, margin expansion and new product launches across plasma and blood management technologies.
• We’ll now examine how this combination of an adjusted earnings beat and margin pressure may reshape Haemonetics’ existing investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Haemonetics Investment Narrative Recap

To own Haemonetics, you have to believe its plasma, hospital and blood management platforms can offset near term margin pressure and product concentration risk. The latest quarter’s adjusted beat, alongside weaker GAAP margins, does not materially change the near term focus on stabilizing profitability while executing on new product launches as the key catalyst, with ongoing dependence on a few U.S. centric franchises remaining the central risk.

The most relevant recent announcement is the expanded FDA labeling for VASCADE MVP XL, which supports larger sheaths in advanced cardiac procedures. This matters because VASCADE is one of Haemonetics’ three core products, and stronger adoption here could help counter concerns about interventional technologies underperforming and provide some support to the margin and growth story investors are watching.

Yet beneath the product momentum, investors should be aware of the possibility that rising competition and a concentrated U.S. revenue base could...

Haemonetics' narrative projects $1.5 billion revenue and $247.6 million earnings by 2029. This requires 5.3% yearly revenue growth and about a $72.2 million earnings increase from $175.4 million today.

Uncover how Haemonetics' forecasts yield a $86.90 fair value, a 60% upside to its current price.

Exploring Other Perspectives

Before this earnings miss on margins, the most optimistic analysts were penciling in around US$1.6 billion of revenue and nearly US$297 million of earnings by 2028, so if you focus on that upbeat view alongside the concentration risk in the core products, it shows how differently you and other shareholders might judge this latest report and why both narratives may need a fresh look.

Explore 2 other fair value estimates on Haemonetics - why the stock might be worth just $86.90!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Haemonetics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Haemonetics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Haemonetics' overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.